Revoke GSR 379E_Reg. Pioglitazone Suspension
Notification - The Drugs and Cosmetics Act, 1940
- Kind: Notification
- Under: The Drugs and Cosmetics Act, 1940
Text of this notification
Tf^tfo^oT$ao-33004/99 ^ ^ ^ S REGD.NO.D.L.-33004/99
3TRH JUI^JIMSI
(Lke (Saxette of ^Jtidia
3TOT«ITTOT
EXTRAORDINARY
•qPT II—T3*S 3—ST-TsPJ^ (i)
PART 11—Section 3—Sub-section (i)
PUBLISHED BY AUTHORITY
K 384] -^^r?it,^«ran:,^nf 31, 2013/Sdraur9, 1935
No. 384| NEW DELHI, WEDNESDAY, JULY 31, 2013/SRAVANA 9, 1935
fcjlfm TTcf MRCIR <*K"M|U| M ÎH'U
(w\m TT? MRCJK <h?M\m fenrPT)
^ f e f t , 3l'^Tf, 2013
w w f ^ 5 2 0 ( 3 T ) _ ^ f % % ^ TOFR ^ TOT fr * ^ sft t% MHlfMdMlH
3 f ^ aft* MHlI^dl^H ^RT W$\ 3WiT < ^ ^ ^ ^ ™ ^ ^ ^
«nf8m*m> fr"^pgT-t afc ^ff% 3W a » % s r f ^ ^ R T f%WT 3 W W
>
^Ri%, fe ^T^K ^T TOT £ ^ s s sft f% ^T t 3W 3 f N ^ * f%#t | g
Qp^Tui, f*r# cfsn f^rr^r % ftw% *rft* 3% fitted ^ w ^rf|cr t
an**** #c ^ R T t. ^ ^ n r ^ ^ ^ * ^ ^ ^ ^ ^ w ! ^
*TTCtft s r fM^m, 1940 (1940 % 23) $t STRT 26 (^) £!TT ^ r T $TfWf ^T WtTT
^ p - s r f ^ R T ^ T T ST.^T.ft- 379 (3T) f^f t^-18 ^T , 2013 % ^ r r
3355 Gl/2013 (11
THE GAZETTE OF INDIA : EXTRAORDINARY fPART II Sf-C. 3(i)|
^f% sfNf̂ r d+41=R ^ T T ^ K *ft# % forfa 19 ̂ n f , 2013 f t 3w sffaflr %
f^fafrr ^ - f%# % f^hR % g | f t srfa # f # r f̂ pBrf̂ r f t f f f sw
SWST % Rt^R f t RkW ff̂ TT «TRT ^f^TT ^TT f ^ J?Rff % T̂«r ̂ T% RWT
f t 3RjrRT fT 5TR> ̂ Tl|iT f^R^T 3 ^ fcfiqfd.l3fi.ft 3}TR ̂ T *TT ^TT
3R: SR akrfsr d=b*f)fl ^ n ^ K sftf f t RHiR^ff % srraTT TR, fe ̂ R ^ R
tRfRT arf^^TT *f. m.^rr.R 379 (3T) f̂ TRT 18 ̂ T, 2013 f t HHfilfed
"MHlR l̂dNlH 3k HMlR^dNlH ^W tf*fr f t f ^ T % *TFR % ;jTR>r %
^ R f t I f fifinfui, R f t rPSTT RCTCW f t 3R T̂R W $tf ̂ 3t f̂Trft |
f f f ^ R t T T R T s f i f t ^ ^ t K s k ^ t f R ^
1. w sftafsr ^T w$\*\ T ^ f f t f%f% n̂" % f%tj ̂ nr >dmK f ^ 3r ̂ t
ff̂ TT ̂ RT Trf |^ l
2. NH-H?dl f t *ffc WRT sreRt'lf fi^filfild s t f ^ ^dNdl ^T FT^ ̂ T t
^T^q- TTTĈ Rf ̂ SRTf % f%tT ^TTf:
• *d^T i ^ R %¥T 3T% TT iplT^R f*TC % fcTR 3T?T ORl-Ml 3 k T$t
f tWf f^Rf ^ H R f t r̂Nr ̂ f f t | , f t m41RHdNlH *T ft
• ^ T fypgfr 3T% ̂ Kd<l f t 3-6 ̂ Tf % ^ ? R % ̂ TSTR H H I R ^ M I H
f t *TCSTT #C ^ H f r l R d l f t HTFfT̂TT ^R> ^Tt|TT <TTff ̂ ^Rtf^R
ff^r r̂r ^i% f% %^r 3^ff 0Rl4Y ^r ? N K T̂TO WT wrq; f^ft
^PT^T f t TfT | l I^R f r f W f t 3T3TT *f <R% W^T ^ F f t T̂ T | ,
^ m-M~lR̂ idM"id ^rr ̂ WK f&n ̂ rnr (# -̂ H I ^ + I U I ^ I ^
• m41R^dNld <p ^r^ % v^t, osrRfcff 3f TĴ -RFT %*TT f t f fe f
„-j. r -vii«|i-^iii|-.'iTri'f*ri'P,,T' .r-n^-^-nr-^^inpT-
'^Wrtfr'-i^H nil""1
""-nrr
http://fcfiqfd.l3fi.ft
[vf\t] \\.—wrs 3(j)J •qj^T =m TT^Fra : 3WTWT
# ^ «U«M"1 nil ̂ + )^ i^ % ^ T £ , T̂T ^THT^ sr̂ r ̂ n* ̂ S ^ P T I
f l ^S TtPNf ^T^mi< *̂ Hd*J wf%cT * | W % HPT 9F5 t%*TT T̂RT
Mi^HVidNln % mv ^ T ^ R fsrc sffr; ^ wzm ^ r ^frflm- <pT
pn" | i
[•qjT. u 4-01 /2011 -"skft'/f^ate]
MINISTRY OF HEALTH AND FAMILY WELFARE
(Department of Health and Family Welfare)
NOTIFICATION
New Delhi, the 31st July, 2013
G.S..R. 520(E).—,Whereas the Central Government was satisfied that the use of
the drug Pioglitazone and all drug formulations containing Piogiitazone was likely to
involve risk to human beings and whereas safer alternatives to the said drug are
available;
Whereas, the Central Government was satisfied that it was necessary and
expedient to regulate by way of suspension, the manufacture for sale, sale and
distribution of the said drug in the country in public interest, and accordingly in exercise
of the powers conferred by section 26A of the Drugs and Cosmetic Act, 1940 (23 of
1940), the Central Government suspended the manufacture for sale, sale and
distribution of Pioglitazone and all formulations containing Pioglitazone for human use
through the notification number G.S.R. 379 (E) dated 18th June, 2013;
Whereas, the Drugs Technical Advisory Board has examined the issue of
suspension of manufacture and sale of the said drug on 19th July, 2013 and has
recommended that the suspension of the drug should be revoked and allowed to be
marketed subject to certain conditions the manufacturers shall mention on their package
insert and promotional literature of the drug;
Now, therefore, on the basis of the recommendations of the Drugs Technical
Advisory Board, the Central Government hereby revokes the notification G.S.R. 379(E)
dated 18th June, 2013 subject to the following conditions as recommended by the Drugs
Technical Advisory Board:-
/
THE GAZETTE OF INDIA : EXTRAORDINARY [PART II -Sue. 3(i)|
"Pioglitazone and all formulations containing Pioglitazone for human use is
allowed to be manufactured for sale, sale and distribution subject to the condition
that the manufacturers shall mention the following on their package insert and
promotional literature of the drug;
1. The drug should not be used as first line of therapy for diabetes.
2. The manufacturer should clearly mention following box warning in
bold red letters.
Advice for healthcare professionals:
• Patients with active bladder cancer or with a history of
bladder cancer, and those with uninvestigated haematuria,
should not receive pioglitazone
• Prescribers should review the safety and efficacy of
pioglitazone in individuals after 3-6 months of treatment to
ensure that only patients who are deriving benefit continue to
be treated. Pioglitazone should be stopped in patients who
do not respond adequately to treatment (eg, reduction in
glycosylated haemoglobin, HbA1c)
• Before starting pioglitazone, the following known risk factors
for development of bladder cancer should be assessed in
individuals: age, current or past history of smoking, exposure
to some occupational or chemotherapy agents such as
cyclophosphamide, or previous irradiation of the pelvic region
• Use in elderly patients should be considered carefully before
and during treatment because the risk of bladder cancer
increases with age. Elderly patients should start on the
lowest possible dose and be regularly monitored because of
the risks of bladder cancer and heart failure associated with
pioglitazone."
[F. No. 4-01/2011-DC/Piogl]
ARUNK. PANDA, Jt. Secy.
Printed by the Manager, Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.
„|„_.—^vt-Jlt-y+r- ^ T p r r i n